Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs
Taysha Gene Therapies (Nasdaq: TSHA) announced a conference call on October 25, 2022, at 8:00 AM ET to discuss Astellas Pharma’s strategic investment in two gene therapy programs: TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Taysha Gene Therapies (Nasdaq: TSHA) announced a conference call on October 25, 2022, at 8:00 AM ET to discuss Astellas Pharma’s strategic investment in two gene therapy programs: TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN). This investment aims to bolster the development of AAV-based therapies targeting rare and large patient populations suffering from monogenic diseases of the central nervous system (CNS). For details, visit Taysha's webcast.
Details
News Market Reaction – TSHA
The recorded move for TSHA in the trading session of this news was +97.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call and webcast on Tuesday, October 25 at 8:00 AM ET
DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will host a conference call and webcast with slides to discuss Astellas Pharma’s strategic investment to support the development of two of Taysha’s AAV-based gene therapy programs, TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN), on Tuesday, October 25, 2022, at 8:00 AM Eastern Time.
| Conference Call Details | |
| Tuesday, October 25, at 8:00 AM Eastern Time / 7:00 AM Central Time | |
| Toll Free: | 877-407-0792 |
| International: | 201-689-8263 |
| Conference ID: | 13734026 |
| Webcast: | https://ir.tayshagtx.com/news-events/events-presentations |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com
Media Contact:
Carolyn Hawley
Evoke Canale
carolyn.hawley@evokegroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.